Turnstone Biologics, Corp.
7
0
1
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
57.1%
4 terminated/withdrawn out of 7 trials
33.3%
-53.2% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
Role: collaborator
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
Role: collaborator
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
Role: lead
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
Role: lead
This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers
Role: lead
MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma
Role: lead
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
Role: lead
All 7 trials loaded